ºÚÁÏÍø

Viking Therapeutics (NASDAQ: VKTX) is set to present at the Stifel Healthcare Conference 2020, with CEO Brian Lian, Ph.D., delivering insights on the company's innovative therapies for metabolic and endocrine disorders. The virtual event will occur from November 16-18, 2020, with Viking's presentation scheduled for 11:40 a.m. PST on November 17, 2020. Investors can access the live webcast on Viking's website, where a replay will also be available post-conference. Viking is advancing its clinical programs, which include VK2809 and VK0214, targeting significant health issues.

Viking Therapeutics (NASDAQ: VKTX) reported its Q3 financial results with a net loss of $9.3 million, or $0.13 per share, compared to a loss of $5.7 million last year. Key developments include ongoing enrollment in the Phase 2b VOYAGE study for VK2809 targeting non-alcoholic steatohepatitis (NASH) and the initiation of a Phase 1 trial for VK0214, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The company ended the quarter with approximately $255 million in cash, supporting further clinical advancements despite challenges posed by the COVID-19 pandemic.

Viking Therapeutics (NASDAQ: VKTX) will announce its third quarter 2020 financial results on October 28, 2020. The announcement follows an upcoming conference call scheduled for 4:30 p.m. ET that same day to discuss the results and corporate updates. Interested parties can join via phone or by visiting the company's website for a live webcast. Viking is known for developing innovative therapies for metabolic and endocrine disorders, including VK2809 for treating non-alcoholic steatohepatitis (NASH) and VK0214 for X-linked adrenoleukodystrophy (X-ALD).

Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 1 clinical trial for VK0214, an orally available thyroid receptor beta agonist aimed at treating X-linked adrenoleukodystrophy (X-ALD). Following FDA clearance of its IND application, the trial will assess the safety, tolerability, and pharmacokinetics of VK0214 in healthy subjects. Preclinical findings indicate that VK0214 may significantly reduce very long chain fatty acids (VLCFAs), which are implicated in X-ALD. The company aims to begin a Phase 1b study in X-ALD patients upon successful completion of the initial trial.

Viking Therapeutics (NASDAQ: VKTX) announced participation in four investor conferences in September 2020. The events include the Citi's 15th Annual BioPharma Conference on September 9-10, Morgan Stanley Global Healthcare Conference on September 14-16, Cantor Fitzgerald Virtual Global Healthcare Conference from September 15-17, and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21-23. The Cantor Fitzgerald and Oppenheimer presentations will be available via webcast on the company's website. Viking is focused on developing therapies for metabolic and endocrine disorders.

Viking Therapeutics (NASDAQ: VKTX) announced promising results from its Phase 2 study of VK2809 for non-alcoholic fatty liver disease (NAFLD) presented at the Digital International Liver Congress 2020. The 12-week study showed a median reduction of 45.4% in liver fat content at Week 16 for VK2809-treated patients, compared to 18.7% for placebo. Notably, 70.4% of VK2809 patients were responders, achieving ≥30% reduction in liver fat. The findings indicate VK2809's potential as a leading treatment for NASH, providing the basis for future dosing strategies and ongoing development in the Phase 2b VOYAGE study.

Viking Therapeutics, Inc. (VKTX) announced the presentation of new data from its 12-week Phase 2 study of VK2809 for patients with non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C at the Digital International Liver Congress 2020. The study successfully met its primary and secondary endpoints, with median relative reductions in liver fat between 53.8% and 60%, and response rates of up to 100%. New efficacy data at Week 16 will be discussed, along with 12-week results stratified by patient characteristics. The VOYAGE study is ongoing for non-alcoholic steatohepatitis (NASH).

Viking Therapeutics (VKTX) reported Q2 2020 financial results, highlighting a net loss of $9.6 million, or $0.13 per share, compared to a loss of $7.7 million in Q2 2019. R&D expenses rose to $7.8 million due to clinical study costs. The company is advancing its clinical trials, including the Phase 2b VOYAGE trial for VK2809 in NASH and initiating a Phase 1 study for VK0214 after filing an IND. Viking ended the quarter with $263 million in cash, supporting its ongoing development efforts and upcoming milestones.

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The William Blair Biotech Focus Conference will take place virtually from August 4-6, 2020, involving 1-on-1 meetings. Additionally, the BTIG Virtual Biotechnology Conference is scheduled for August 10-11, 2020, featuring a fireside chat on August 11 at 3:30 p.m. Eastern and 1-on-1 meetings. Viking is focused on developing therapies for metabolic disorders, including VK2809 for NASH and VK5211 for improving lean body mass.